Basilea Pharmaceutica AG (SIX: BSLN.SW) AI-Powered Stock Analysis
See how Basilea Pharmaceutica AG scores across key metrics like financial growth, valuation, and market position on the SIX, using AI-driven evaluation.
BSLN.SW●SIX
HealthcareBiotechnology
CHF64.60
CHF1.00(1.52%)
Swiss Market opens in 6h 12m
Basilea Pharmaceutica AG (SIX: BSLN.SW) AI-Powered Stock Analysis
See how Basilea Pharmaceutica AG scores across key metrics like financial growth, valuation, and market position on the SIX, using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full DisclaimerBasilea Pharmaceutica AG (SIX: BSLN.SW) Stock Overall Grade
Basilea Pharmaceutica AG's grade for its SIX listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Basilea Pharmaceutica AG's overall SIX stock rating.
Forecast
A+Score
96/100Financial Growth
A+Score
100/100Fundamental Growth
AScore
87/100Key Ratios
A+Score
91/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
98/100Analyst Consensus
C+Score
50/100Basilea Pharmaceutica AG (SIX: BSLN.SW) AI-Powered Stock Analysis
On the SIX, BSLN.SW demonstrates Good performance with an overall Forecast Score of 96/100 (A+), reflecting high confidence in its potential. Financial Growth (100/100, A+) and Fundamental Growth (87/100, A) highlight its stability, while Key Ratios (91/100, A+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (98/100, A+), the SIX-listed stock shows competitive strength. Analyst Consensus (50/100, C+) suggests High divergence in outlook.(SIX: BSLN.SW) Component Analysis Explained
Understand the key factors behind each Basilea Pharmaceutica AG (SIX: BSLN.SW) stock grade, including financials, comparisons, and forecasts.